StockMarketWire.com - Pharmaceutical giant AstraZeneca said its non-small-cell lung cancer drug candidate had been been given a regulatory nod for priority review in the US.
Tragrisso had received acceptance for a supplemental new drug application in the US for the treatment of patients with early-stage non-small cell lung cancer after complete tumour resection with curative intent, the company said.
US health regulators were expected to deliver their regulatory decision during the first quarter of 2021, the company said.
Story provided by StockMarketWire.com
Shares Magazine
Shares is the leading weekly publication for retail investors. It is packed with investment ideas, news and educational material to help build and run portfolios and get more from your money.
Investor Events
Shares puts on free Investor Events throughout the year across the country. They provide an opportunity for investors to learn more about companies on the stock market and hear from a range of investment experts including fund managers and Shares journalists.